Inclusion Criteria:  Patient with diagnosis of moderate-to-severe chronic plaque psoriasis documented in the medical chart. Patient who need systemic biologic therapy and qualify for treatment with an IL-23p19 inhibitor. Tildrakizumab must be the anti-IL-23p19 selected therapy before including the patient in the study. Patient aged 18 years or older at the time of patient recruitment. Patient who have provided written informed consent (if required by country regulations).  Exclusion Criteria:  Patients unable to comply with the requirements of the study (fulfilling of the study questionnaires) or who, in the opinion of the study physician, should not participate in the study. Patients included in a clinical trial.